Lumida
/AXGN
⌘K
AxoGen Inc

AxoGen Inc

AXGN
$42.16USD+0.74%+0.31 today

MARKET CAP

2.3B

P/E (TTM)

FWD P/E

DAY RANGE

$40 – $43

52W RANGE

$15
$53

AI Summary

Stalk
StalkMedium

AXGN exhibited a terminal Capitulation (Final Flush) bar on extreme volume, signaling forced liquidation is ending and setting up a potential reflex rally within the long-term uptrend. Medium-term directional asymmetry shifts bullish given the terminal pattern, but price remains extended below the 9- and 21-day EMAs without evidence of stabilization. Execution should be deferred (Stalk) and focused on pullback absorption or early signs of a hold near intermediate moving averages before buying.

  • Q2 2026 revenue $69.7M (+23.1% YoY) reflects sustained sales momentum.
  • Breast procedure sales up 47% YoY show increased surgeon adoption.
  • Gross margin fell to 72.7% from 74.2% YoY due to higher production costs.
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2021FY 2022FY 2023FY 2024FY 2025TREND
Sales, Adj.$127.4M$138.6M$159.0M$187.3M$225.2M
YoY %+13.4%+8.8%+14.7%+17.8%+20.2%
P / Sales3.0x3.0x1.9x3.9x6.7x
EV / Sales3.5x3.6x2.3x4.3x6.9x
Gross Profit, Adj.$104.4M$108.8M$121.9M$142.0M$167.4M
YoY %+15.1%+4.2%+12.0%+16.5%+17.9%
Margin %82.0%78.5%76.6%75.8%74.3%
EV / Gross Profit4.3x4.5x3.0x5.6x9.3x
EBITDA, Adj.$-22.5M$-26.6M$-17.0M$3.4M$-874,000
YoY %-13.9%-18.4%+36.2%+120.3%-125.4%
Margin %-17.6%-19.2%-10.7%1.8%-0.4%
EV / EBITDA-20.0x-18.6x-21.6x232.6x-1790.1x
EBIT$-25.4M$-29.7M$-21.5M$-3.3M$-7.8M
YoY %-9.6%-16.9%+27.8%+84.7%-138.8%
Margin %-20.0%-21.4%-13.5%-1.8%-3.5%
EV / EBIT-17.7x-16.7x-17.1x-243.9x-199.3x
Net Income$-27.0M$-28.9M$-21.7M$-10.0M$-15.7M
YoY %-13.4%-7.3%+25.0%+54.1%-57.6%
Net Margin-21.2%-20.9%-13.7%-5.3%-7.0%
EPS (GAAP)-$0.65-$0.69-$0.51-$0.23-$0.34
YoY %-8.3%-6.2%+26.1%+54.9%-47.8%